TY - JOUR
T1 - Characterization of lytic Pseudomonas aeruginosa bacteriophages via biological properties and genomic sequences
AU - Karumidze, Natia
AU - Thomas, Julie A.
AU - Kvatadze, Nino
AU - Goderdzishvili, Marina
AU - Hakala, Kevin W.
AU - Weintraub, Susan T.
AU - Alavidze, Zemphira
AU - Hardies, Stephen C.
N1 - Funding Information:
Acknowledgments This project was supported by GRDF/GNSF08/ 532 no. 0408 grant to N.K., ISTC G-1369 to Z.A., and a UTHSCSA pilot project grant to S.C.H. Mass spectrometry analyses were conducted in the UTHSCSA Institutional Mass Spectrometry Laboratory, and bioinformatic analysis was conducted with assistance from the UTHSCSA Bioinformatics Center. The phages described in this paper later may be used in phage preparations produced by Eliava Institute and Ltd “Eliava Biopreparations” for treatment of different purulent infections.
PY - 2012/6
Y1 - 2012/6
N2 - Pseudomonas aeruginosa is an important cause of infections, especially in patients with immunodeficiency or diabetes. Antibiotics are effective in preventing morbidity and mortality from Pseudomonas infection, but because of spreading multidrug-resistant bacterial strains, bacteriophages are being explored as an alternative therapy. Two newly purified broad host range Pseudomonas phages, named vB-Pae-Kakheti25 and vB-Pae-TbilisiM32, were characterized as candidates for use in phage therapy. Morphology, host range, growth properties, thermal stability, serology, genomic sequence, and virion composition are reported. When phages are used as bactericides, they are used in mixtures to overcome the development of resistance in the targeted bacterial population. These two phages are representative of diverse siphoviral and podoviral phage families, respectively, and hence have unrelated mechanisms of infection and no cross-antigenicity. Composing bactericidal phage mixtures with members of different phage families may decrease the incidence of developing resistance through a common mechanism.
AB - Pseudomonas aeruginosa is an important cause of infections, especially in patients with immunodeficiency or diabetes. Antibiotics are effective in preventing morbidity and mortality from Pseudomonas infection, but because of spreading multidrug-resistant bacterial strains, bacteriophages are being explored as an alternative therapy. Two newly purified broad host range Pseudomonas phages, named vB-Pae-Kakheti25 and vB-Pae-TbilisiM32, were characterized as candidates for use in phage therapy. Morphology, host range, growth properties, thermal stability, serology, genomic sequence, and virion composition are reported. When phages are used as bactericides, they are used in mixtures to overcome the development of resistance in the targeted bacterial population. These two phages are representative of diverse siphoviral and podoviral phage families, respectively, and hence have unrelated mechanisms of infection and no cross-antigenicity. Composing bactericidal phage mixtures with members of different phage families may decrease the incidence of developing resistance through a common mechanism.
KW - Bacteriophage
KW - Host range
KW - Phage resistance
KW - Phage therapy
KW - Pseudomonas aeruginosa
UR - http://www.scopus.com/inward/record.url?scp=84867299046&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84867299046&partnerID=8YFLogxK
U2 - 10.1007/s00253-012-4119-8
DO - 10.1007/s00253-012-4119-8
M3 - Article
C2 - 22562168
AN - SCOPUS:84867299046
SN - 0175-7598
VL - 94
SP - 1609
EP - 1617
JO - Applied Microbiology and Biotechnology
JF - Applied Microbiology and Biotechnology
IS - 6
ER -